Therefore, we determined the effect of reducing endogenous tau expression on cognitive deficits in transgenic mice expressing human amyloid precursor protein (hAPP)
This paper illustrates the Science Practices standards (SP.1-SP.4).
The authors take observed phenomena, note that they have yet to be fully explored, and carefully form testable hypotheses about their role in the development of Alzheimer’s disease.
In their study, the researchers combine knowledge from earlier research using mouse models to study the molecular basis of the disease with two main observations:
(1) Tau is known to build up in Alzheimer’s disease patients, and
(2) a higher than normal level of tau protein results in a higher risk for developing the disease.
They hypothesize that changing the level of tau will result in less severe disease symptoms, which they carefully test in well-designed experiments, choosing powerful methods to collect and analyze data and to control for as many variables as possible.
Finally, they incorporate their findings into a general model for tau working together with amyloid-β to cause the symptoms of Alzheimer’s disease.
http://apcentral.collegeboard.com/apc/public/repository/cbscs-science-standards-2009.pdf (Page iii)